Scancell Holdings Plc Lindy Durrant appointed CEO of Scancell (8098G)
July 28 2021 - 12:00PM
UK Regulatory
TIDMSCLP
RNS Number : 8098G
Scancell Holdings Plc
28 July 2021
28 July 2021
Scancell Holdings plc
("Scancell" or the "Company")
Professor Lindy Durrant appointed CEO of Scancell
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
is pleased to announce that Professor Lindy Durrant, founder, Board
Director and Chief Scientific Officer of Scancell has been
appointed Chief Executive Officer of Scancell Holdings plc with
immediate effect. Professor Durrant was previously co-CEO of the
Company. Dr Cliff Holloway has decided to step down as a Board
Director and CEO, also with immediate effect. The Board would like
to thank Cliff for his commitment over the last three years during
which time the Company has made substantial progress.
Professor Lindy Durrant, said: "I believe Scancell has an
unrivalled pipeline of products and I, along with the rest of the
team at Scancell, intend to continue to drive our pipeline through
the clinic as we focus on accelerating the development of what we
believe to be our most commercially promising assets."
Dr Cliff Holloway, said: "Since I joined Scancell in early 2018
we've built and financed the Company to the point where it has a
strong and diverse pipeline and it can now embark on its next phase
of growth. I'm proud to have led Scancell during this pivotal time.
The Company is now stronger than ever and I look forward to
following its continued progress."
Dr John Chiplin, Executive Chairman, Scancell Holdings plc,
commented: "As a founder and CSO, Lindy is the driving force behind
Scancell's internationally recognised science. The Board firmly
believes her strategic insight and commitment to moving products
into the clinic as well as her strong leadership skills will
deliver significant value to the business and to shareholders."
"We are very grateful to Cliff for all his hard work over the
last three years at Scancell. The Company is now on a sound
financial footing with the infrastructure in place for the next
stage of its growth. The Board and I wish Cliff all the best for
the future."
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Panmure Gordon (UK) Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Ben Maddison (Healthcare Investment
Banking)
Nick Adams (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Natalie Garland-Collins
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its technology platforms, ImmunoBody(R) ,
Moditope(R) and AvidiMab(TM) , with four products in multiple
cancer indications and development of a vaccine for COVID-19.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
CD4 and CD8 T cells with the ability to identify, target and
eliminate cancer cells. These cancer vaccines have the potential to
be used as monotherapy or in combination with checkpoint inhibitors
and other agents. The Directors believe that this platform has the
potential to enhance tumour destruction, prevent disease recurrence
and extend survival.
-- SCIB1, Scancell's lead product, is being developed for the
treatment of metastatic melanoma. In a Phase 1/2 clinical trial,
survival with SCIB1 treatment appears superior to historical
survival rates, with 14 of 16 resected patients receiving 2-4 mg
doses of SCIB1 surviving for more than five years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours.
DNA vaccine against COVID-19: As research data emerges, it is
becoming increasingly clear that the induction of potent and
activated T cells play a critical role in the development of
long-term immunity and clearance of virus-infected cells. Initial
research is underway and Scancell anticipates initiating a Phase 1
clinical trial known as COVIDITY during 2021.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). Examples of such
modifications are citrullination, an enzyme-based conversion of
arginine to citrulline, and homocitrullination (or carbamylation),
in which lysine residues are converted to homocitrulline.
Expression of peptides containing these modifications have been
demonstrated to induce potent CD4 cytotoxic t cells to eliminate
cancer. Previous pre-clinical studies have demonstrated that
conjugation of these Moditope(R) peptides to Amplivant(R) enhances
anti-tumour immune responses 10-100 fold and resulted in highly
efficient tumour eradication, including protection against tumour
recurrence.
-- Modi-1 consists of two citrullinated vimentin peptides and
one citrullinated enolase peptide each conjugated to Amplivant(R).
Vimentin and enolase peptides are highly expressed in triple
negative breast, ovarian, head and neck, and renal cancer, as well
as many other cancers.
AvidiMab(TM) has broad potential to increase the avidity or
potency of any therapeutic monoclonal antibody (mAb) including
those being developed for autoimmune diseases, as well as cancer.
Scancell's development pipeline includes mAbs against specific
tumour-associated glycans (TaGs) with superior affinity and
selectivity profiles, that have now been further engineered using
the Company's AvidiMab(TM) technology; this confers the Scancell
anti-TaG mAbs with the ability to directly kill tumour cells. The
Company has entered into three non-exclusive research agreements
with leading antibody technology companies to evaluate the
Company's anti-TaG mAbs including those enhanced with the
AvidiMab(TM) technology.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADKFBQPBKDBOB
(END) Dow Jones Newswires
July 28, 2021 12:00 ET (16:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024